Nexvet expands veterinary biologics research team


By Dylan Bushell-Embling
Monday, 15 September, 2014

Nexvet Biopharma has added two former CSL (ASX:CSL) scientists to its veterinary biologics research team.

CSL’s former director of preclinical cell biology, Dr Samantha Busfield, and former director of analytical biochemistry, Dr Dallas Hartman, have both joined Nexvet’s veterinary biologics research centre in Melbourne.

The centre is designed to bolster Nexvet’s product pipelines and support the company’s existing veterinary drug programs. Nexvet specialises in species-specific biologic treatments for companion animals, produced with its PETization platform.

“I’m delighted to welcome two such experienced research managers to the Nexvet team,” Nexvet chief science officer Dr David Gearing commented. “Their breadth of experience in research and development in biopharmaceuticals will be invaluable.”

He said Nexvet is putting together a team of scientists with diverse biopharma backgrounds for its research activities.

“We are excited about our work on new animal therapies, building on our pioneering research in this field to build a world-class centre for veterinary biologics research,” Gearing said.

In April, Nexvet raised US$31.5 million ($34.9 million) to fund clinical programs for treatment candidates for canine pain, feline pain and canine inflammation.

Related News

Cancer drug eliminates bone metastasis in lab models

Researchers have developed a novel treatment that is specific to breast cancer bone metastasis...

TGA rejects Alzheimer's drug due to safety concerns

The TGA determined that the demonstrated efficacy of lecanemab in treating Alzheimer's did...

Defective sperm doubles pre-eclampsia risk in IVF patients

A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd